Research Efforts Underway for RARA+ MDS and AML | Supplements And Featured Publications

Investigators Explore RARA Overexpression With Tamibarotene in Higher-Risk MDS

June 28, 2022

Risk stratification for patients with myelodysplastic syndrome have afforded those with asymptomatic or low-risk disease treatment pathways that can be navigated using a variety of patient characteristics. However, treatment algorithms for patients with higher-risk disease are limited to allogeneic transplant or treatment with hypomethylating agents.

SELECT-MDS-1: Review of Study Design and Objectives

June 28, 2022

Gustavo Rivero, MD, comments on the ongoing SELECT-MDS-1 trial and as well as reviewing the adverse events of the potential combination of tamibarotene with azacitidine in patients with higher-risk MDS.